President · Neumora Therapeutics, Inc. (NMRA)

Joshua Pinto

A named executive officer of Neumora Therapeutics in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$6,743,238

Salary $645,000Stock awards $0Bonus $989,350

FY2024: $4,630,573

1st of 4 named executive officers at Neumora Therapeutics by FY2025 total.

4 named officers on file for Neumora Therapeutics, FY2025

Joshua Pinto’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Neumora Therapeutics’s whole pay program stands against its peers

  • Neumora Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NMRA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed January 1, 1900 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Joshua Pinto’s full pay file as a PDF — free

More than this page: up to 10 years of Joshua’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Joshua Pinto compensation by year

Neumora Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Neumora Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$508,654$645,000
Bonus$0$989,350
Stock awards$1,535,950$0
Option awards$2,391,900$4,643,438
Non-equity incentive$193,289$464,400
Pension and deferred compensation$0$0
All other$780$1,050
Total$4,630,573$6,743,238

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Neumora Therapeutics, Inc. DEF 14A filed January 1, 1900, accession 0001193125-26-161489, and prior-year filings.

How this page was built: the Neumora Therapeutics, Inc. filed document, accession 0001193125-26-161489. Every figure is read from that document and cited to the page and table it appears in. Filed January 1, 1900.

$4.6M
$6.7M
FY24
FY25
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU63,750$114,113—
Option92,084—$0.72
Option3,000,000—$0.72
Option47,793—$0.72
Option30,004—$0.72
Option37,174—$0.72

Per the Outstanding Equity Awards at Fiscal Year-End table in Neumora Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

33 Form 4 lines since the FY2025 proxy (filed January 1, 1900)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-08-20Grant or award derivative—500,000$0.00500,000
2026-02-17Sale—5,967$3.5457,783
2026-01-08Grant or award derivative—1,200,000$0.001,200,000
2025-05-28Disposition to the issuer derivative—270,828—0
2025-05-28Disposition to the issuer derivative—223,034—0
2025-05-28Grant or award derivative—223,034—223,034
2025-05-28Grant or award derivative—3,000,000—3,000,000
2025-05-28Disposition to the issuer derivative—720,084—0

The 8 most recent of 33 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Neumora Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Joshua Pinto · this pagePresident$6,743,238
Paul BernsChief Executive Officer$4,562,461
Bill AuroraChief Strategy Officer$3,302,000
Henry GosebruchFormer President and Chief Executive Officer$1,319,273

The full Neumora Therapeutics compensation record

free company brief

This page is one person within Neumora Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Neumora Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Joshua Pinto's compensation dossier · One-time report. No refunds.